- 专利标题: ARF-P19, a novel regulator of the mammalian cell cycle
-
申请号: US129855申请日: 1998-08-06
-
公开(公告)号: US6046032A公开(公告)日: 2000-04-04
- 发明人: Charles J. Sherr , Dawn Quelle , Martine F. Roussel , Frederique Zindy
- 申请人: Charles J. Sherr , Dawn Quelle , Martine F. Roussel , Frederique Zindy
- 申请人地址: TN Memphis
- 专利权人: St. Jude Children's Research Hospital
- 当前专利权人: St. Jude Children's Research Hospital
- 当前专利权人地址: TN Memphis
摘要:
The INK4A (MTS1, CDKN2) gene encodes a specific inhibitor (InK4a-p16) of the cyclin D-dependent kinases CDK4 and CDK6. InK4a-p16 can block these kinase from phosphorylating the retinoblastoma protein (pRb), preventing exit from the G1 phase of the cell cycle. Deletions and mutations involving the gene encoding InK4a-p16, INK4A, occur frequently in cancer cells, implying that INK4a-p16, like pRb, suppresses tumor formulation. However, a completely unrelated protein (ARF-p19) arises in major part from an alternative reading frame of the mouse INK4A gene. Expression of an ARF-p19 cDNA (SEQ ID NO:1) in rodent fibroblasts induces both G1 and G2 phase arrest. Economical reutilization of protein coding sequences in this manner is without precedent in mammalian genomes, and the unitary inheritance of INK4a-p16 and ARF-p19 may reflect a dual requirement for both proteins in cell cycle control.
公开/授权文献
信息查询